Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study.

Trial Profile

Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 May 2009

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic asthma; Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2009 Results published in Clinical and Experimental Allergy.
    • 04 Feb 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 04 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top